Key result
Obesity with diabetes or prediabetes during anthracycline chemotherapy linked to ~74% higher major cardiovascular events risk.
Why the study?
Anthracycline-based chemotherapy carries notable risks of cardiotoxicity, but how different body mass index values and glycemic status influence the risk of MACE remained to be assessed.
Do obesity and diabetes/prediabetes increase the risk of MACE in chemotherapy-naïve adult patients with cancer treated with anthracyclines?
Cohort
Do obesity and diabetes/prediabetes increase the risk of MACE in chemotherapy-naïve adult patients with cancer treated with anthracyclines?
In cancer patients receiving anthracyclines, concurrent obesity and diabetes/prediabetes significantly increases the risk of MACE and heart failure hospitalization, highlighting the need for tailored cardio-oncology risk assessment.
Answers are grounded in this paper and cite their sources.
Supports refined cardio-oncology risk assessment incorporating obesity and diabetes; hypothesis-generating for prospective validation in anthracycline recipients.
BACKGROUND: Anthracycline-based chemotherapy is a vital treatment for various cancers but carries notable risks of cardiotoxicity. This study aimed to assess how different body mass index values and glycemic status influence the risk of major adverse cardiovascular events (MACE) in chemotherapy-naïve adult patients with cancer treated with anthracyclines. METHODS: ). Glycemic status was classified as normoglycemic or diabetes/prediabetes (diabetes: hemoglobin A1c ≥6.5% or fasting glucose ≥126 mg/dL; prediabetes: hemoglobin A1c 5.7%-6.4% or fasting glucose 100-125 mg/dL). RESULTS: Over a median follow-up of 8.7 years, 985 (8.64%) patients experienced MACE. Obesity was significantly associated with an increased risk of MACE (hazard ratio [HR], 1.38 [95% CI, 1.10-1.73], reference: underweight/normal weight) and heart failure hospitalization, and diabetes/prediabetes also significantly predicted MACE (HR, 1.28 [95% CI, 1.10-1.50], reference: normoglycemic). Notably, overweight (HR, 0.85 [95% CI, 0.80-0.91]) and obesity (HR, 0.85 [95% CI, 0.74-0.96]) were associated with lower risk of all-cause mortality. Joint analysis revealed that patients with both obesity and diabetes/prediabetes had the highest risk of MACE (HR, 1.74 [95% CI, 1.28-2.37]) and heart failure hospitalization (HR, 1.99 [95% CI, 1.41-2.81]). CONCLUSIONS: In patients with cancer undergoing anthracycline-based chemotherapy, both body mass index and glycemic status significantly affect cardiovascular risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes, emphasizing the need for tailored risk assessment and management.
No takes yet. Share an insight, caveat, or question.
Cheang et al. (2025) conducted a cohort in Cancer treated with anthracyclines. Concurrent obesity and diabetes/prediabetes vs. Underweight/normal weight and normoglycemic was evaluated on Major adverse cardiovascular events (MACE) (HR 1.74, 95% CI 1.28-2.37). Concurrent obesity and diabetes/prediabetes in patients receiving anthracycline chemotherapy was associated with the highest risk of major adverse cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: